Research

The main areas of research of our imaging centers focus on monitoring therapy of chronic inflammatory diseases of the central nervous system (multiple sclerosis) as well as on the evaluation of the latest therapy methods in the treatment of peripheral arterial occlusive disease (PAOD).

Research Neuroradiology.

Multiple sclerosis is our focus of research in neuroradiology. Encephalitis disseminata is a chronic inflammatory disease that damages nerve fibers in the brain. The aim of our efforts is to evaluate new therapeutic methods as well as to test the latest imaging methods and to establish them in clinical routine.

Below you will find a selection of multicenter, international studies in which our Radiological Care Center is involved:

• Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
• A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Patient With Relapsing Remitting Multiple Sclerosis (CASTING)
• An open label single-arm study to evaluate the effectiveness and safety of ocrelizumab in patients with early stage relapsing remitting multiple sclerosis (Ensemble)
• A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
• A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis (OPERA)
• Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis
   

Research Interventional Radiology.

Rapid technological developments of the last decade have led to minimally invasive therapies for peripheral arterial occlusive disease (PAOD) becoming a standard procedure. To ensure that our patients always benefit from medical progress, we have been researching intensively for many years in evaluation of novel therapy methods so that we can offer them at an early stage.

Below you will find a selection of multicenter, international studies in which our Radiological Care Center is involved:

• Global Study of a Drug-coated Balloon to Treat Obstructive SFA and/or Popliteal Lesions (ILLUMENATE)
• ELUVIATM Drug-eluting Stent Versus Zilver® PTX® Stent (IMPERIAL)
• SAMBA EU Femoropopliteal Trial
• First-in-human Evaluation of the SELUTION DCB, a Novel Sirolimus Coated Balloon in Peripheral Arteries
• Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System® in Below the Knee Arteries (TOBA II BTK)
• Tack Optimized Drug Coated Balloon Angioplasty Study of The Tack Endovascular SystemTM in Femoropopliteal Arteries (TOBA III)
• Safety and Efficacy oft he SurVeilTM Drug-Coated Balloon (TRANSCEND)

A selection of publications from our Radiological Care Center on the treatment of peripheral arterial occlusive disease.

• Sustainable Antirestenosis Effect With a Low-Dose Drug-Coated Balloon: The ILLUMENATE European Randomized Clinical Trial 2-Year Results. Brodmann M, Werner M, Meyer DR, Reimer P, Krüger K, Granada JF, Jaff MR, Schroeder H; ILLUMENATE EU RCT Investigators. JACC Cardiovasc Interv. 2018 Dec 10;11(23):2357-2364.

• A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Gray WA, Keirse K, Soga Y, Benko A, Babaev A, Yokoi Y, Schroeder H, Prem JT, Holden A, Popma J, Jaff MR, Diaz-Cartelle J, Müller-Hülsbeck S; IMPERIAL investigators. Lancet. 2018 Oct 27;392(10157):1541-1551. doi: 10.1016/S0140-6736(18)32262-1.

• Self-Expanding Versus Balloon-Expandable Stents for Iliac Artery Occlusive Disease: The Randomized ICE Trial. Krankenberg H, Zeller T, Ingwersen M, Schmalstieg J, Gissler HM, Nikol S, Baumgartner I, Diehm N, Nickling E, Müller-Hülsbeck S, Schmiedel R, Torsello G, Hochholzer W, Stelzner C, Brechtel K, Ito W, Kickuth R, Blessing E, Thieme M, Nakonieczny J, Nolte T, Gareis R, Boden H, Sixt S. JACC Cardiovasc Interv. 2017 Aug 28;10(16):1694-1704.

• A Pilot Study of Femoropopliteal Artery Revascularisation with a Low Dose Paclitaxel Coated Balloon: Is Predilatation Necessary? Schroeder H, Meyer DR, Lux B, Ruecker F, Martorana M, Miller LE, Duda S. Eur J Vasc Endovasc Surg. 2017 Sep;54(3):348-355.
• Low-Dose Paclitaxel-Coated Versus Uncoated Percutaneous Transluminal Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease: One-Year Results of the ILLUMENATE European Randomized Clinical Trial (Randomized Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon). Schroeder H, Werner M, Meyer DR, Reimer P, Krüger K, Jaff MR, Brodmann M; ILLUMENATE EU RCT Investigators. Circulation. 2017 Jun 6;135(23):2227-2236.
• German Center Subanalysis of the LEVANT 2 Global Randomized Study of  the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease. Schmidt A, Zeller T, Müller-Hülsbeck S, Sixt S, Schröder H, Weiss N, Ketelsen D, Ricke J, Steiner S, Rosenfield K. J Endovasc Ther. 2016 Jun;23(3):409-16
• Two-year results of a low-dose drug-coated balloon for revascularization of the femoropopliteal artery: outcomes from the ILLUMENATE first-in-human study. Schroeder H, Meyer DR, Lux B, Ruecker F, Martorana M, Duda SH. Catheter Cardiovasc Interv. 2015 Aug;86(2):278-86.
• Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. Tepe G, Schnorr B, Albrecht T, Brechtel K, Claussen CD, Scheller B, Speck U, Zeller T. JACC Cardiovasc Interv. 2015 Jan;8(1 Pt A):102-8.
• Heparin-bonded stent-graft for the treatment of TASC II C and D femoropopliteal lesions: the Viabahn-25 cm trial. Zeller T, Peeters P, Bosiers M, Lammer J, Brechtel K, Scheinert D, Rastan A, Noory E, Beschorner U. J Endovasc Ther. 2014 Dec;21(6):765-74.
• The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. Scheinert D, Duda SH, Zeller T, Krankenberg H, Ricke J, Bosiers M, Tepe G, Naisbitt S, Rosenfield K. JACC Cardiovasc Interv. 2014 Jan;7(1):10-9.
• Prospective, multicenter European study of the GORE flow reversal system for providing neuroprotection during carotid artery stenting. Nikas D, Reith W, Schmidt A, Duda SH, Mathias K, Cremonesi A, Dill H, Formgren J, Pieniazek P, Musialek P, Hornung M, Sievert H, Reimers B. Catheter Cardiovasc Interv. 2012 Dec 1;80(7):1060-8.
• Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Oliva V, Tielbeek A, Anderson J, Wiesinger B, Tepe G, Lansky A, Jaff MR, Mudde C, Tielemans H, Beregi JP. J Endovasc Ther. 2006 Dec;13(6):701-10.